arrow
W

Wenxian Wang

fudan university
H指数:30
被引数:3,126

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tislelizumab plus sitravatinib or anlotinib as maintenance therapy in extensive-stage small-cell lung cancer: Results of two prospective phase II studies

替利珠单抗联合西达维替尼或安洛替尼作为广泛期小细胞肺癌的维持治疗:两项前瞻性II期研究的结果

2025-11-010
OA
ENGOT-en11/GOG-3053/KEYNOTE-B21: A phase III study of pembrolizumab or placebo in combination with adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer

ENGOT-en11/GOG-3053/KEYNOTE-B21: 一项关于帕博利珠单抗或安慰剂联合辅助化疗,且根据情况联合或不联合放疗,在 newly diagnosed、high-risk endometrial cancer 患者中进行的 III 期研究

2024-09-010
PRE
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China

人类表皮生长因子受体2抗体-药物偶联物诱导的间质性肺疾病/肺炎跨学科管理的临床最佳实践: 中国专家共识

CANCER
IF5.1
2024-08-021
PRE